DGRO vs IBB
iShares Core Dividend Growth ETF vs iShares Biotechnology ETF
- • DGRO has the lower expense ratio at 0.08% vs 0.44% for IBB.
- • DGRO pays a higher dividend yield (1.95%).
Side-by-side metrics
| Metric | DGRO | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.08% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.95% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $41.23B | $9.09B |
YTD return | 11.68% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.68 | 0.69 |
P/E ratio | 23.53 | 24.79 |
Last price | $77.00 | $196.62 |
Inception | — | — |
Issuer | iShares | iShares |
DGRO top holdings
| JNJ | Johnson & Johnson | 3.12% |
| ABBV | AbbVie Inc | 3.05% |
| JPM | JPMorgan Chase & Co | 3.03% |
| AAPL | Apple Inc | 2.76% |
| MSFT | Microsoft Corp | 2.67% |
| XOM | Exxon Mobil Corp | 2.60% |
| AVGO | Broadcom Inc | 2.55% |
| HD | The Home Depot Inc | 2.33% |
| PG | Procter & Gamble Co | 2.26% |
| PM | Philip Morris International Inc | 2.08% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About DGRO
DGRO (iShares Core Dividend Growth ETF) is US stocks with sustained dividend growth. Managed by iShares, the fund carries $41.2B in assets under management, an expense ratio of 0.08%, a dividend yield of 1.95%. Its largest holding is Johnson & Johnson (JNJ), which represents 3.1% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 6.5%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.